Emerging Axonal Variants of Guillain Barré Syndrome “ AMAN and AMSAN “ as a Part of COVID-19 Sequalae | ||
| The Medical Journal of Basrah University | ||
| Article 8, Volume 40, Issue 2, June 2022, Pages 151-162 PDF (565.42 K) | ||
| Document Type: Research Paper | ||
| DOI: 10.33762/mjbu.2023.139791.1125 | ||
| Authors | ||
| Hassan Ala Farid* 1; Nareen Hiakaz Bedoyan* 2; Haithem Jawad Kadhum3; Ali Raheem Hashim4; Zaineb Adil Yaqoob3 | ||
| 1Institute of Medical and Biomedical Education, St. George’s University of London, London, United Kingdom | ||
| 2Medical physiology Resident in College of medicine – university of Basra and Basra health directorate | ||
| 3Department of Physiology, College of Medicine, University of Basrah, Basrah, Iraq | ||
| 4Department of Medicine, College of Medicine, University of Basrah, Basrah, Iraq | ||
| Abstract | ||
| Background: Guillain-Barré syndrome (GBS) is an immune-mediated peripheral nerve disease. Its frequency was noticed to have increased during the COVID-19 period. Based on electrophysiological studies, the most common type of this disease is the demyelinating type. However, axonal types have also been seen. Methods: A large, analytical, cross-sectional study involving 2523 patients over a one-year period was conducted in Basrah, southern Iraq, to evaluate the neurophysiological changes for peripheral neuropathies following COVID-19 infection using nerve conduction studies and needle electromyography. The current study aims to evaluate the prevalence, clinical, and neurophysiological characteristics of patients with axonal variants of GBS. Results and conclusions: The study found that the axonal variants of GBS represent about 10% of the total reported GBS in the governorate, and they are developed in about 1 in 1000 patients attending the neurology and neurophysiology clinics who had a history of COVID-19 infection | ||
| Keywords | ||
| GBS; AMAN; AMSAN; BASRAH; IRAQ | ||
|
Supplementary Files
|
||
|
Statistics Article View: 160 PDF Download: 144 |
||
